Trial Profile
A Phase II placebo-controlled trial of SMT C1100 in Duchenne Muscular Dystrophy patients in US and Europe
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2018
Price :
$35
*
At a glance
- Drugs Ezutromid (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Summit Therapeutics
- 27 Jun 2018 According to a Summit Therapeutics media release, based on the results of the PhaseOut DMD 48-week data, the company has discontinued this drug development program, as, its primary and secondary endpoints has not been Met.
- 27 Jun 2018 Status changed from planning to withdrawn prior to enrolment, according to a Summit Therapeutics media release.
- 09 Aug 2016 According to Summit Plc media release, planned initiation date changed from 1 Jun 2016 to 1 Jun 2017.